Drug-resistant Mycobacterium Tuberculosis Among Nepalese Patients at a Tuberculosis Referral Center

Overview

Journal PLoS One

Specialties General Medicine
Science

Date 2024 May 6

PMID 38709710

Authors

Arun Bahadur Chand

Ajaya Basnet

Bhagwan Maharjan

Ganesh Rai

Yadav Prasad Joshi

Lok Raj Bhatt

Bindu Sen

Shiba Kumar Rai

Affiliations

Soon will be listed here.

Abstract

Background: Multidrug-resistant tuberculosis (MDR-TB), characterized by isoniazid and rifampicin resistance, is caused by chromosomal mutations that restrict treatment options and complicate tuberculosis management. This study sought to investigate the prevalence of pre-extensively drug-resistant (pre-XDR) and extensively drug-resistant (XDR) tuberculosis, as well as mutation pattern, in Nepalese patients with MDR/rifampicin-resistant (RR)-TB strains.

Methods: A cross-sectional study was conducted on MDR/RR-TB patients at the German Nepal Tuberculosis Project from June 2017 to June 2018. The MTBDRsl line probe assay identified pre-XDR-TB and XDR-TB. Pre-XDR-TB included MDR/RR-TB with resistance to any fluoroquinolone (FLQ), while XDR-TB included MDR/RR-TB with resistance to any FLQ and at least one additional group A drug. Mutation status was determined by comparing bands on reaction zones [gyrA and gyrB for FLQ resistance, rrs for SILD resistance, and eis for low-level kanamycin resistance, according to the GenoType MTBDRsl VER 2.0, Hain Lifescience GmbH, Nehren, Germany definition of pre-XDR and XDR] to the evaluation sheet. SPSS version 17.0 was used for data analysis.

Results: Out of a total of 171 patients with MDR/RR-TB, 160 had (93.57%) had MTBC, of whom 57 (35.63%) had pre-XDR-TB and 10 (6.25%) had XDR-TB. Among the pre-XDR-TB strains, 56 (98.25%) were FLQ resistant, while 1 (1.75%) was SLID resistant. The most frequent mutations were found at codons MUT3C (57.14%, 32/56) and MUT1 (23.21%, 13/56) of the gyrA gene. One patient had SLID resistant genotype at the MUT1 codon of the rrs gene (100%, 1/1). XDR-TB mutation bands were mostly detected on MUT1 (30%, 3/10) of the gyrA and rrs, MUT3C (30%, 3/10) of the gyrA, and MUT1 (30%, 3/10) of the rrs.

Conclusions: Pre-XDR-TB had a significantly higher likelihood than XDR-TB, with different specific mutation bands present in gyrA and rrs genes.

References

Dalton T, Cegielski P, Akksilp S, Asencios L, Caoili J, Cho S . Prevalence of and risk factors for resistance to second-line drugs in people with multidrug-resistant tuberculosis in eight countries: a prospective cohort study. Lancet. 2012; 380(9851):1406-17. PMC: 11019390. DOI: 10.1016/S0140-6736(12)60734-X. View

Conkle-Gutierrez D, Kim C, Ramirez-Busby S, Modlin S, Mansjo M, Werngren J . Distribution of Common and Rare Genetic Markers of Second-Line-Injectable-Drug Resistance in Mycobacterium tuberculosis Revealed by a Genome-Wide Association Study. Antimicrob Agents Chemother. 2022; 66(6):e0207521. PMC: 9211393. DOI: 10.1128/aac.02075-21. View

Che Y, Song Q, Yang T, Ping G, Yu M . Fluoroquinolone resistance in multidrug-resistant independent of fluoroquinolone use. Eur Respir J. 2017; 50(6). DOI: 10.1183/13993003.01633-2017. View

Yuan X, Zhang T, Kawakami K, Zhu J, Li H, Lei J . Molecular characterization of multidrug- and extensively drug-resistant Mycobacterium tuberculosis strains in Jiangxi, China. J Clin Microbiol. 2012; 50(7):2404-13. PMC: 3405621. DOI: 10.1128/JCM.06860-11. View

Chen Y, Yuan Z, Shen X, Wu J, Wu Z, Xu B . Resistance to Second-Line Antituberculosis Drugs and Delay in Drug Susceptibility Testing among Multidrug-Resistant Tuberculosis Patients in Shanghai. Biomed Res Int. 2016; 2016:2628913. PMC: 5019859. DOI: 10.1155/2016/2628913. View

Ginsburg A, Grosset J, Bishai W . Fluoroquinolones, tuberculosis, and resistance. Lancet Infect Dis. 2003; 3(7):432-42. DOI: 10.1016/s1473-3099(03)00671-6. View

Gardee Y, Dreyer A, Koornhof H, Omar S, da Silva P, Bhyat Z . Evaluation of the GenoType MTBDR Version 2.0 Assay for Second-Line Drug Resistance Detection of Mycobacterium tuberculosis Isolates in South Africa. J Clin Microbiol. 2016; 55(3):791-800. PMC: 5328447. DOI: 10.1128/JCM.01865-16. View

Brossier F, Veziris N, Truffot-Pernot C, Jarlier V, Sougakoff W . Molecular investigation of resistance to the antituberculous drug ethionamide in multidrug-resistant clinical isolates of Mycobacterium tuberculosis. Antimicrob Agents Chemother. 2010; 55(1):355-60. PMC: 3019671. DOI: 10.1128/AAC.01030-10. View

Malik S, Willby M, Sikes D, Tsodikov O, Posey J . New insights into fluoroquinolone resistance in Mycobacterium tuberculosis: functional genetic analysis of gyrA and gyrB mutations. PLoS One. 2012; 7(6):e39754. PMC: 3386181. DOI: 10.1371/journal.pone.0039754. View

10.

Dutt R, Singh R, Majhi J, Basu G . Status of drug resistant tuberculosis among patients attending a tuberculosis unit of West Bengal: A record based cross-sectional study. J Family Med Prim Care. 2022; 11(1):84-89. PMC: 8930159. DOI: 10.4103/jfmpc.jfmpc_576_21. View

11.

Lee E, Min J, Kang J, Kim S, Kim J, Kim Y . Age-stratified anti-tuberculosis drug resistance profiles in South Korea: a multicenter retrospective study. BMC Infect Dis. 2020; 20(1):446. PMC: 7310538. DOI: 10.1186/s12879-020-05157-6. View

12.

Kozinska M, Brzostek A, Krawiecka D, Rybczynska M, Zwolska Z, Augustynowicz-Kopec E . [MDR, pre-XDR and XDR drug-resistant tuberculosis in Poland in 2000-2009]. Pneumonol Alergol Pol. 2011; 79(4):278-87. View

13.

Singhal P, Dixit P, Singh P, Jaiswal I, Singh M, Jain A . A study on pre-XDR & XDR tuberculosis & their prevalent genotypes in clinical isolates of Mycobacterium tuberculosis in north India. Indian J Med Res. 2016; 143(3):341-7. PMC: 4892081. DOI: 10.4103/0971-5916.182625. View

14.

Hawkey P . Mechanisms of quinolone action and microbial response. J Antimicrob Chemother. 2003; 51 Suppl 1:29-35. DOI: 10.1093/jac/dkg207. View

15.

Sharma R, Sharma S, Singh B, Mittal A, Kumar P . High degree of fluoroquinolone resistance among pulmonary tuberculosis patients in New Delhi, India. Indian J Med Res. 2019; 149(1):62-66. PMC: 6507539. DOI: 10.4103/ijmr.IJMR_1220_17. View

16.

Ahmad N, Javaid A, Syed Sulaiman S, Ming L, Ahmad I, Khan A . Resistance patterns, prevalence, and predictors of fluoroquinolones resistance in multidrug resistant tuberculosis patients. Braz J Infect Dis. 2015; 20(1):41-7. PMC: 9425347. DOI: 10.1016/j.bjid.2015.09.011. View

17.

Bradner L, Robbe-Austerman S, Beitz D, Stabel J . Chemical decontamination with N-acetyl-L-cysteine-sodium hydroxide improves recovery of viable Mycobacterium avium subsp. paratuberculosis organisms from cultured milk. J Clin Microbiol. 2013; 51(7):2139-46. PMC: 3697694. DOI: 10.1128/JCM.00508-13. View